8-K: Viewbix Secures $1.4M in Private Placement, Amends Quantum X Labs Acquisition

Viewbix Inc. has entered into an amended securities purchase agreement to raise approximately $1.4 million through a private placement, alongside an updated agreement to acquire 85.01% of Quantum X Labs Ltd.

Summary

• Viewbix Inc. (the Company) has entered into an Amended and Restated Securities Purchase Agreement as of January 1, 2026, replacing a previous agreement from November 5, 2025.
• The Company will sell and issue an aggregate of 800,000 shares of Common Stock or pre-funded warrants, along with common warrants to purchase up to 640,000 shares of Common Stock.
• The combined purchase price is $1.75 per Private Placement Share and accompanying Common Warrant, or $1.74999 per Pre-Funded Warrant and accompanying Common Warrant.
• Gross proceeds from the Private Placement Offering are expected to be approximately $1.4 million, with a potential additional $1.68 million if all Common Warrants are exercised in cash.
• The private placement and the acquisition of Quantum X Labs Ltd. are expected to close during the first quarter of 2026, subject to customary closing conditions and stockholder approval.
• The Company has amended its acquisition agreement for Quantum X Labs Ltd., now agreeing to acquire at least 85.01% of its share capital, down from the initially planned 100%.
• A Registration Rights Agreement, dated November 5, 2025, requires the Company to file a resale registration statement within 30 calendar days after the Closing Date and have it declared effective within 60 to 90 calendar days.
• L.I.A. Pure Capital Ltd. will receive a $70,000 cash fee and a warrant to purchase 32,000 shares as an advisory commission, conditioned upon the closing of the Private Placement Offering.
• The Company will repay $200,000 of an outstanding loan to L.I.A. Pure Capital Ltd. in connection with the closing of the Private Placement Offering.

Sentiment

Score: 6

Explanation: The filing outlines a capital raise and a strategic acquisition, which are generally positive for growth and future prospects. However, the associated dilution, contingencies for closing, and reduction in net proceeds due to advisory fees and loan repayment introduce elements of caution, leading to a moderately positive sentiment.

Positives

• Secured approximately $1.4 million in gross proceeds from the private placement, providing capital for general corporate purposes and potential acquisitions.
• Potential for an additional $1.68 million in gross proceeds if all common warrants are exercised in cash.
• The strategic acquisition of a significant stake (85.01%) in Quantum X Labs Ltd. is moving forward, which could enhance the Company's business prospects.
• The Registration Rights Agreement provides a clear path for investors to resell their securities, potentially increasing liquidity and investor confidence.

Negatives

• The issuance of 800,000 shares/pre-funded warrants and 640,000 common warrants will result in dilution for existing shareholders.
• The Company was unable to acquire 100% of Quantum X Labs Ltd. as initially intended, settling for 85.01%.
• The closing of both the private placement and the acquisition is contingent on obtaining stockholder approval and other customary conditions, introducing execution risk.
• A $200,000 loan repayment to the advisor and a $70,000 cash commission will reduce the net proceeds from the private placement.

Risks

• The closing of the Private Placement Offering and the Acquisition are subject to various conditions and contingencies, including stockholder approval, which may not be satisfied.
• The effectiveness of the resale registration statement could be delayed by a full review by the SEC or a shutdown/suspension of U.S. federal government/SEC operations.
• The issuance of the Securities may result in substantial dilution of the outstanding shares of Common Stock for existing shareholders.
• Hedging activities by purchasers of the Securities could negatively impact the market price of the Company's publicly-traded securities.
• The Company must maintain its listing on the Trading Market and secure listing for the newly issued shares and warrant shares.
• Failure to reserve a sufficient number of Common Stock shares could hinder the exercise of warrants.

Future Outlook

The Company expects to close the Private Placement Offering and the acquisition of Quantum X Labs Ltd. during the first quarter of 2026, subject to various conditions including stockholder approval. It also plans to file a resale registration statement within 30 calendar days of the closing and aims for it to be effective within 60-90 days. The Company cautions against undue reliance on these forward-looking statements due to inherent risks and contingencies.

Management Comments

• Amihay Hadad, Chief Executive Officer, signed the Form 8-K on behalf of Viewbix Inc.

Industry Context

This filing indicates Viewbix Inc.'s strategic move to raise capital and expand its business through the acquisition of Quantum X Labs Ltd. While specific industry trends are not detailed, the transaction suggests a focus on growth and potentially technology-driven expansion, aligning with broader industry trends of consolidation and capital infusion for innovation.

Comparison to Industry Standards

• The private placement structure, including common stock/pre-funded warrants and accompanying warrants, is a common financing mechanism for growth-stage companies seeking capital from accredited investors.
• The requirement for stockholder approval for the issuance of securities and the acquisition is standard practice for transactions that could significantly impact ownership or company structure, particularly under Nasdaq rules.
• The inclusion of a Registration Rights Agreement is typical in private placements to provide investors with a path to liquidity for their restricted securities, comparable to similar deals in the small-cap and micro-cap market segments.

Corporate Governance

Related Party Transactions

• L.I.A. Pure Capital Ltd. (Lead Investor/Advisor) will receive a cash fee of $70,000 and a warrant to purchase 32,000 shares of Common Stock as a commission for advisory services related to the Private Placement Offering.
• The Company will repay $200,000 of an outstanding loan owed to L.I.A. Pure Capital Ltd. (pursuant to an Amended and Restated Facility Agreement dated July 22, 2024) upon the closing of the Private Placement Offering.

Stakeholder Impact

• **Shareholders**: Will experience dilution from the issuance of new shares and warrants. However, the capital raise and strategic acquisition could enhance long-term company value.
• **Investors (Purchasers)**: Will acquire shares and warrants at a specified price, with registration rights providing a path to liquidity. They are indemnified by the Company for certain losses related to the registration statement.
• **L.I.A. Pure Capital Ltd. (Advisor)**: Benefits from a cash commission, warrants, and repayment of a portion of its outstanding loan, indicating a favorable outcome for this related party.
• **Quantum X Labs Ltd. (Acquired Entity)**: Will become a significant part of Viewbix Inc., with 85.01% of its share capital being acquired, indicating a strategic integration.

Next Steps

• Close the Private Placement Offering and the acquisition of 85.01% of Quantum X Labs Ltd. during the first quarter of 2026.
• Obtain stockholder approval for the Private Placement and the Acquisition, as required by Nasdaq rules.
• File a resale registration statement with the SEC within 30 calendar days after the Closing Date.
• Work to have the registration statement declared effective within 60 calendar days (or 90 days if reviewed by the SEC) after its filing.
• Maintain the listing of the Common Stock on its Trading Market and apply to list all newly issued shares and warrant shares.
• File a preliminary proxy statement for stockholder approvals at the next annual meeting.

Key Dates

Recommendation

The private placement provides necessary capital and facilitates a strategic acquisition, which are positive steps for Viewbix Inc.'s growth trajectory. However, the significant dilution for existing shareholders, the contingencies surrounding stockholder approval for both the capital raise and the acquisition, and the reduction in net proceeds due to advisory fees and loan repayment introduce notable risks. A 'Hold' recommendation is appropriate, balancing the potential for future upside from strategic expansion against these immediate uncertainties and dilutive effects. Investors should monitor the successful completion of the closing conditions and the integration of Quantum X Labs.

Keywords

Private Placement, Securities Purchase Agreement, Warrants, Common Stock, Capital Raise, Acquisition, Quantum X Labs, SEC Filing, Registration Rights, Dilution, Stockholder Approval